巴塞隆纳主动免疫治疗学论坛促进。2011 年 5 月 11 日-13 日，西班牙巴塞罗那。
Phacilitate Barcelona active immunotherapeutics forum. 11-13 May 2011, Barcelona, Spain.
机构信息
Carolina Urologic Research Center/Atlantic Urology Clinics, Myrtle Beach, SC 29572, USA.
出版信息
Immunotherapy. 2011 Aug;3(8):931-2. doi: 10.2217/imt.11.90.
The era of active immunotherapy has now been successfully ushered into the clinical realm of advanced prostate cancer. The successful clinical trial development and US FDA approval of sipuleucel-T (Provenge®) has revamped the therapeutic paradigm for advanced prostate cancer. Nonetheless, physician and patient education as well as regulatory pathways and manufacturing efficiencies are still required in order to optimize patient care. These topics were covered at the Phacilitate Barcelona Active Immunotherapeutics Forum.
主动免疫疗法的时代现已成功地进入晚期前列腺癌的临床领域。Sipuleucel-T（Provenge®）的成功临床试验开发和美国 FDA 批准彻底改变了晚期前列腺癌的治疗模式。然而，为了优化患者护理，仍需要进行医生和患者教育以及监管途径和制造效率方面的工作。这些主题在 Phacilitate 巴塞罗那主动免疫治疗论坛上进行了讨论。
Zotero 插件